UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

     
þ   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2014
     
    OR
     
o   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM                      TO     

 

COMMISSION FILE NUMBER: 814-00802

 

HORIZON TECHNOLOGY FINANCE CORPORATION

(Exact name of registrant as specified in its charter)

 

DELAWARE   27-2114934
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
     
312 Farmington Avenue    
Farmington, CT   06032
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code (860) 676-8654

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o .

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer” and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer o   Accelerated filer þ   Non-accelerated filer o   Smaller Reporting Company o
        (Do not check if a smaller reporting company)    

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ .

 

As of November 4, 2014, the Registrant had 9,626,175 shares of common stock, $0.001 par value, outstanding. 

 

 

 

 
 

 

HORIZON TECHNOLOGY FINANCE CORPORATION

 

FORM 10-Q

TABLE OF CONTENTS

 

    Page
PART I  
Item 1. Consolidated Financial Statements 3
     
  Consolidated Statements of Assets and Liabilities as of September 30, 2014 and December 31, 2013 (unaudited) 3
  Consolidated Statements of Operations for the three and nine months ended September 30, 2014 and 2013 (unaudited) 4
  Consolidated Statements of Changes in Net Assets for the three and nine months ended September 30, 2014 and 2013 (unaudited) 5
  Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2014 and 2013 (unaudited) 6
  Consolidated Schedules of Investments as of September 30, 2014 and December 31, 2013 (unaudited) 7
  Notes to the Consolidated Financial Statements (unaudited) 15
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 34
Item 3. Quantitative And Qualitative Disclosures About Market Risk 48
Item 4. Controls and Procedures 48
     
PART II  
Item 1. Legal Proceedings 49
Item 1A. Risk Factors 49
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 49
Item 3. Defaults Upon Senior Securities 49
Item 4. Mine Safety Disclosures 49
Item 5. Other Information 49
Item 6. Exhibits 49
  Signatures 50
EX-31.1    
EX-31.2    
EX-32.1    
EX-32.2    

 

2
 

 

PART I: FINANCIAL INFORMATION

 

Item 1. Consolidated Financial Statements

 

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Statements of Assets and Liabilities (Unaudited)

(In thousands, except share data)

 

   September 30,
2014
   December 31,
2013
 
Assets          
Non-affiliate investments at fair value (cost of $208,727 and $234,310, respectively) (Note 4)  $204,694   $221,284 
Cash   15,194    25,341 
Investments in money market funds   800    1,188 
Restricted investments in money market funds   3,368    5,951 
Interest receivable   4,905    4,240 
Other assets   3,622    5,733 
Total assets  $232,583   $263,737 
           
Liabilities          
Borrowings (Note 6)  $87,902   $122,343 
Distributions payable   3,321    3,315 
Base management fee payable (Note 3)   355    439 
Incentive fee payable (Note 3)   800    852 
Other accrued expenses   1,778    953 
Total liabilities   94,156    127,902 
Commitments and Contingencies (Notes 7 and 8)          
           
Net assets          
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2014 and December 31, 2013        
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 9,625,274 and 9,608,949 shares outstanding as of September 30, 2014 and December 31, 2013, respectively   10    10 
Paid-in capital in excess of par   155,202    154,975 
Accumulated (distributions in excess of) undistributed net investment income   (975)   1,463 
Net unrealized depreciation on investments   (4,033)   (13,026)
Net realized loss on investments   (11,777)   (7,587)
Total net assets   138,427    135,835 
Total liabilities and net assets  $232,583   $263,737 
Net asset value per common share  $14.38   $14.14 

 

See Notes to Consolidated Financial Statements

 

3
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Statements of Operations (Unaudited)

(In thousands, except share data)

 

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2014   2013   2014   2013 
Investment income                    
Interest income on non-affiliate investments  $6,786   $8,225   $21,714   $23,979 
Fee income on non-affiliate investments   953    487    2,257    889 
Total investment income   7,739    8,712    23,971    24,868 
Expenses                    
Interest expense   1,495    2,189    7,326    5,886 
Base management fee1 (Note 3)   1,038    1,266    3,380    3,836 
Performance based incentive fee1 (Note 3)   800    872    1,207    2,465 
Administrative fee (Note 3)   335    287    872    889 
Professional fees   607    284    2,721    977 
General and administrative   223    247    823    793 
Total expenses   4,498    5,145    16,329    14,846 
Net investment income before excise tax   3,241    3,567    7,642    10,022 
Provision for excise tax   (40)   (80)   (120)   (160)
Net investment income   3,201    3,487    7,522    9,862 
                     
Net realized and unrealized gain (loss) on investments                    
Net realized gain (loss) on investments   2,325    (5,566)   (4,190)   (5,839)
Net unrealized (depreciation) appreciation on investments   (766)   5,967    8,993    3,996 
Net realized and unrealized gain (loss) on investments   1,559    401    4,803    (1,843)
                     
Net increase in net assets resulting from operations  $4,760   $3,888   $12,325   $8,019 
Net investment income per common share  $0.33   $0.36   $0.78   $1.03 
Net increase in net assets per common share  $0.50   $0.41   $1.28   $0.84 
Distributions declared per share  $0.345   $0.345   $1.035   $1.035 
Weighted average shares outstanding   9,623,468    9,584,376    9,619,133    9,577,912 

 

(1) During the three months ended September 30, 2013, the Advisor waived $144 of base management fee. During the nine months ended September 30, 2014 and 2013, the Advisor waived $238 and $144 of base management fee, respectively. During the nine months ended September 30, 2014, the Advisor waived $107 of performance based incentive fee. Had these expenses not been waived, the base management fee for the three months ended September 30, 2013 would have been $1,410. Had these expenses not been waived, the base management fee for the nine months ended September 30, 2014 and 2013 would have been $3,618 and $3,980, respectively, and performance based incentive fee for the nine months ended September 30, 2014 would have been $1,314.

 

See Notes to Consolidated Financial Statements

 

4
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Statements of Changes in Net Assets (Unaudited)

(In thousands, except share data)

 

       Common   Paid-In
Capital in
Excess of
   Accumulated 
(Distribution
in Excess of)
Undistributed 
Net
Investment
   Net Unrealized
Depreciation
on
   Net Realized
Loss on
   Total Net 
   Shares   Stock   Par   Income   Investments   Investments   Assets 
Balance at December 31, 2012    9,567,225   $10   $154,384   $1,428   $(10,772)  $(78)  $144,972 
Net increase in net assets resulting from operations                9,862    3,996    (5,839)   8,019 
Issuance of common stock under dividend reinvestment plan    21,768        312                312 
Distributions declared                (9,919)           (9,919)
Balance at September 30, 2013    9,588,993   $10   $154,696   $1,371   $(6,776)  $(5,917)  $143,384 
                                    
Balance at December 31, 2013    9,608,949   $10   $154,975   $1,463   $(13,026)  $(7,587)  $135,835 
Net increase in net assets resulting from operations                7,522    8,993    (4,190)   12,325 
Issuance of common stock under dividend reinvestment plan    16,325        227                227 
Distributions declared                (9,960)           (9,960)
Balance at September 30, 2014    9,625,274   $10   $155,202   $(975)  $(4,033)  $(11,777)  $138,427 

 

See Notes to Consolidated Financial Statements

 

5
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Statements of Cash Flows (Unaudited)

(In thousands)

 

   For the Nine Months Ended 
   September 30, 
   2014   2013 
Cash flows from operating activities:          
Net increase in net assets resulting from operations  $12,325   $8,019 
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:          
Amortization of debt issuance costs   2,370    902 
Net realized loss on investments   4,190    5,629 
Net unrealized appreciation on investments   (8,993)   (3,996)
Purchase of investments   (66,836)   (69,143)
Principal payments received on investments   83,906    55,954 
Proceeds from sale of investments   5,119    39 
Changes in assets and liabilities:          
Decrease (increase) in investments in money market funds   388    (22,459)
Decrease (increase) in restricted investments in money market funds   2,583    (3,568)
Increase in interest receivable   (168)   (160)
Increase in end-of-term payments   (497)   (1,148)
Decrease in unearned loan income   (796)   (1,190)
(Increase) decrease in other assets   (259)   458 
Increase (decrease) in other accrued expenses   825    (143)
Decrease in base management fee payable   (84)   (76)
(Decrease) increase in incentive fee payable   (52)   17 
Net cash provided by (used in) operating activities   34,021    (30,865)
           
Cash flows from financing activities:          
Proceeds from issuance of Asset-Backed Notes       90,000 
Repayment of Asset-Backed Notes   (34,441)    
Distributions paid   (9,727)   (9,599)
Net decrease in credit facilities       (46,020)
Debt issuance costs       (2,125)
Net cash (used in) provided by financing activities   (44,168)   32,256 
Net (decrease) increase in cash   (10,147)   1,391 
           
Cash:          
Beginning of period   25,341    1,048 
End of period  $15,194   $2,439 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $4,968   $4,982 
           
Supplemental non-cash investing and financing activities:          
Warrant investments received & recorded as unearned loan income  $501   $626 
Distributions payable  $3,321   $3,308 

 

See Notes to Consolidated Financial Statements

 

6
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments (Unaudited)

September 30, 2014

(In thousands)

 

         Principal   Cost of   Fair 
Portfolio Company (1)  Sector  Type of Investment (3)(4)(7)(10)(11)  Amount   Investments (6)   Value 
Debt Investments — 141.3% (9)               
Debt Investments — Life Science — 29.0% (9)               
Argos Therapeutics, Inc. (5)  Biotechnology  Term Loan (9.25% cash (Libor + 9.25%; Floor 9.25%;  $5,000   $4,867   $4,867 
      Ceiling 10.75%), 5% ETP, Due 10/1/18)               
Inotek Pharmaceuticals Corporation (2)  Biotechnology  Term Loan (11.00% cash, 3.00% ETP, Due 10/1/16)   3,152    3,130    3,130 
New Haven Pharmaceuticals, Inc. (2)  Biotechnology  Term Loan (11.50% cash, 3.00% ETP, Due 5/1/16)   1,451    1,424    1,424 
      Term Loan (11.50% cash, 3.00% ETP, Due 5/1/16)   484    480    480 
Sample6, Inc. (2)  Biotechnology  Term Loan (9.50% cash (Libor + 9.50%; Floor   1,555    1,548    1,548 
      9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18)               
   Biotechnology  Term Loan (9.50% cash (Libor + 9.50%; Floor 9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18)   945    910    910 
Sunesis Pharmaceuticals, Inc. (2)(5)   Biotechnology  Term Loan (8.95% cash, 3.75% ETP, Due 10/1/15)   870    868    868 
      Term Loan (9.00% cash, 3.75% ETP, Due 10/1/15)   1,306    1,293    1,293 
Xcovery Holding Company, LLC (2)   Biotechnology  Term Loan (12.50% cash, Due 8/1/15)   488    487    487 
      Term Loan (12.50% cash, Due 8/1/15)   767    766    766 
      Term Loan (12.50% cash, Due 10/1/15)   153    153    153 
Accuvein, Inc. (2)  Medical Device  Term Loan (10.40% cash (Libor + 9.90%; Floor   4,000    3,952    3,952 
      10.40%; Ceiling 11.90%), 5.00% ETP, Due 8/1/17)               
IntegenX, Inc. (2)  Medical Device  Term Loan (10.75% cash (Libor + 10.25%; Floor   3,750    3,680    3,680 
      10.75%; Ceiling 12.75%), 3.50% ETP, Due 7/1/18)               
Lantos Technologies, Inc. (2)  Medical Device  Term Loan (10.50% cash (Libor + 10.00%; Floor   3,500    3,420    3,420 
      10.50%; Ceiling 12.00%), 3.00% ETP, Due 2/1/18)               
Mederi Therapeutics, Inc. (2)  Medical Device  Term Loan (10.75% cash (Libor + 10.25%; Floor   3,000    2,966    2,966 
      10.75%; Ceiling 12.75%), 4.00% ETP, Due 7/1/17)               
      Term Loan (10.75% cash (Libor + 10.25%; Floor   3,000    2,966    2,966 
      10.75%; Ceiling 12.75%), 4.00% ETP, Due 7/1/17)               
Mitralign, Inc. (2)  Medical Device  Term Loan (12.00% cash, 3.00% ETP, Due 12/31/14)   1,049    1,044    1,044 
      Term Loan (10.88% cash, 3.00% ETP, Due 12/31/14)   743    739    739 
      Term Loan (10.50% cash, 3.00% ETP, Due 12/31/14)   1,100    1,055    1,055 
Tryton Medical, Inc.  Medical Device  Term Loan (10.41% cash (Prime + 7.16%), 2.50% ETP, Due 9/1/16)   3,000    2,973    2,973 
ZetrOZ, Inc.  Medical Device  Term Loan (11.00% cash (Libor + 11.00%; Floor11.00%; Ceiling 12.50%), 3.00% ETP, Due 4/1/18)   1,500    1,425    1,425 
Total Debt Investments — Life Science              40,146    40,146 
Debt Investments — Technology — 81.5% (9)               
Ekahau, Inc. (2)  Communications  Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17)   1,413    1,397    1,397 
      Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17)   471    465    465 
mBlox, Inc. (2)  Communications  Term Loan (11.50% cash (Libor + 11.00%; Floor   5,000    4,965    4,965 
      11.50%; Ceiling 13.00%), 2.5% ETP, Due 7/1/18)               
      Term Loan (11.50% cash (Libor + 11.00%; Floor   5,000    4,965    4,965 
      11.50%; Ceiling 13.00%), 2.5% ETP, Due 7/1/18)               
Overture Networks, Inc. (2)  Communications  Term Loan (10.75% cash, 4.75% ETP, Due 12/1/16)   4,408    4,370    4,370 
      Term Loan (10.75% cash, 4.75% ETP, Due 12/1/16)   2,204    2,181    2,181 
Gwynnie Bee, Inc. (2)  Consumer-related Technologies  Term Loan (11.00% cash (Libor + 10.50%; Floor   2,000    1,963    1,963 
      11.00%; Ceiling 12.50%), 2.0% ETP, Due 11/1/17)               
      Term Loan (11.00% cash (Libor + 10.50%; Floor   1,000    971    971 
      11.00%; Ceiling 12.50%), 2.0% ETP, Due 2/1/18)               
      Term Loan (11.00% cash (Libor + 10.50%; Floor   1,000    979    979 
      11.00%; Ceiling 12.50%), 2.0% ETP, Due 4/1/18)               
Optaros, Inc. (2)   Internet and Media  Term Loan (11.95% cash, 3.00% ETP, Due 10/1/15)   1,031    1,027    1,027 
      Term Loan (11.95% cash, 3.00% ETP, Due 3/1/16)   348    347    347 
SimpleTuition, Inc. (2)  Internet and Media  Term Loan (11.75% cash, Due 3/1/16)   2,719    2,698    2,698 
Nanocomp Technologies, Inc. (2)  Networking  Term Loan (11.50% cash, 3.00% ETP, Due 11/1/17)   1,000    985    985 
Avalanche Technology, Inc. (2)  Semiconductors  Term Loan (10.00% cash, 2.00% ETP, Due 7/1/16)   2,174    2,162    2,162 
      Term Loan (10.00% cash, 2.00% ETP, Due 1/1/18)   2,349    2,318    2,318 
eASIC Corporation (2)  Semiconductors  Term Loan (11.00% cash, 2.50% ETP, Due  4/1/17)   2,000    1,978    1,978 
      Term Loan (10.75% cash, 2.50% ETP, Due 4/1/18)   2,000    1,981    1,981 
InVisage Technologies, Inc. (2)  Semiconductors  Term Loan (12.00% cash (Libor + 11.50%; Floor   2,550    2,465    2,465 
      12.00%; Ceiling 14.00%), 2.0% ETP, Due 4/1/18)               
Kaminario, Inc. (2)  Semiconductors  Term Loan (10.50% cash, 2.50% ETP, Due 11/1/16)   2,644    2,618    2,618 
      Term Loan (10.50% cash, 2.50% ETP, Due 11/1/16)   2,644    2,618    2,618 
Luxtera, Inc. (2)  Semiconductors  Term Loan (10.25% cash, 8.00% ETP, Due 7/1/17)   2,632    2,583    2,583 
      Term Loan (10.25% cash, 8.00% ETP, Due 7/1/17)   1,469    1,460    1,460 
NexPlanar Corporation (2)  Semiconductors  Term Loan (10.50% cash, 2.50% ETP, Due 12/1/16)   2,644    2,623    2,623 
      Term Loan (10.50% cash, 2.50% ETP, Due 12/1/16)   1,763    1,743    1,743 

 

See Notes to Consolidated Financial Statements

 

7
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments (Unaudited)

September 30, 2014

(In thousands)

 

         Principal   Cost of   Fair 
Portfolio Company (1)  Sector  Type of Investment (3)(4)(7)(10)(11)  Amount   Investments (6)   Value 
Xtera Communications, Inc. (2)   Semiconductors  Term Loan (11.50% cash, 14.77% ETP, Due 7/1/15)   5,918    5,754    5,754 
      Term Loan (11.50% cash, 13.65% ETP, Due 2/1/16)   1,645    1,596    1,596 
Construction Software Technologies, Inc. (2)   Software  Term Loan (11.75% cash, 5.00% ETP, Due 10/1/16)   3,825    3,808    3,808 
      Term Loan (11.75% cash, 5.00% ETP, Due 10/1/16)   3,825    3,808    3,808 
Courion Corporation (2)   Software  Term Loan (11.45% cash, Due 10/1/15)   1,640    1,637    1,637 
      Term Loan (11.45% cash, Due 10/1/15)   1,640    1,637    1,637 
Decisyon, Inc. (2)  Software  Term Loan (11.65% cash, 5.00% ETP, Due 9/1/16)   3,290    3,263    3,263 
      Term Loan (11.65% cash, 5.00% ETP, Due 11/1/17)   1,000    984    984 
Lotame Solutions, Inc. (2)  Software  Term Loan (11.50% cash (Libor + 11.50%; Floor   3,410    3,388    3,388 
      11.50%), 5.25% ETP, Due 9/1/17)               
      Term Loan (11.50% cash (Libor + 11.50%; Floor   1,500    1,490    1,490 
      11.50%), 5.25% ETP, Due 9/1/17)               
      Term Loan (11.50% cash (Libor + 11.50%; Floor   2,100    2,068    2,068 
      11.50%), 3.00% ETP, Due 4/1/18)               
Netuitive, Inc. (2)  Software  Term Loan (12.75% cash, Due 7/1/16)   1,780    1,768    1,768 
Raydiance, Inc. (2)  Software  Term Loan (11.50% cash, 2.75% ETP, Due 9/1/16)   4,111    4,083    4,083 
      Term Loan (11.50% cash, 2.75% ETP, Due 9/1/16)   822    809    809 
      Term Loan (11.50% cash, 2.75%, ETP, Due 2/1/18   3,000    2,952    2,952 
Razorsight Corporation (2)  Software  Term Loan (11.75% cash, 3.00% ETP, Due 11/1/16)   1,324    1,312    1,312 
      Term Loan (11.75% cash, 3.00% ETP, Due 8/1/16)   1,188    1,175    1,175 
      Term Loan (11.75% cash, 3.00% ETP, Due 7/1/17)   1,000    986    986 
Social Intelligence Corp. (2)  Software  Term Loan (11.00% cash (Libor + 10.50%; Floor   1,500    1,475    1,475 
      11.00%; Ceiling 13.00%), 3.50% ETP, Due 12/1/17)               
SpringCM, Inc. (2)  Software  Term Loan (11.50% cash (Libor + 11.00%; Floor   4,500    4,406    4,406 
      11.50%; Ceiling 13.00%), 2.00% ETP, Due 1/1/18)               
Sys-Tech Solutions, Inc. (2)  Software  Term Loan (11.65% cash, Due 6/1/16)   6,000    5,902    5,902 
VBrick Systems, Inc. (2)  Software  Term Loan (11.50% cash (Libor + 10.00%; Floor   3,000    2,977    2,977 
      10.50%; Ceiling 13.50%), 5.00% ETP, Due 7/1/17)               
Vidsys, Inc. (2)  Software  Term Loan (11.00% cash, 7.60% ETP, Due 4/1/15)   3,000    2,987    2,987 
Visage Mobile, Inc. (2)  Software  Term Loan (12.00% cash, 3.50% ETP, Due 9/1/16)   731    724    724 
Total Debt Investments — Technology               112,851    112,851 
Debt Investments — Cleantech — 10.5% (9)               
Renmatix, Inc. (2)  Alternative Energy  Term Loan (10.25% cash, 3.00% ETP, Due 2/1/16)   1,377    1,371    1,371 
      Term Loan (10.25% cash, 3.00% ETP, Due 2/1/16)   1,377    1,371    1,371 
      Term Loan (10.25% cash, Due 10/1/16)   3,915    3,891    3,891 
Semprius, Inc. (2)(8)  Alternative Energy  Term Loan (10.25% cash, 2.50% ETP, Due 6/1/16)   2,588    2,587    2,282 
Aurora Algae, Inc. (2)   Energy Efficiency  Term Loan (10.50% cash, 2.00% ETP, Due 5/1/15)   626    625    625 
Rypos, Inc. (2)  Energy Efficiency  Term Loan (11.80% cash, Due 1/1/17)   2,850    2,818    2,818 
      Term Loan (11.80% cash, Due 9/1/17)   1,000    984    984 
Tigo Energy, Inc.  (2)   Energy Efficiency  Term Loan (13.00% cash, 3.16% ETP,  Due 6/1/15)   1,161    1,157    1,157 
Total Debt Investments — Cleantech              14,804    14,499 
Debt Investments — Healthcare information and services — 20.3% (9)            
LifePrint Group, Inc. (2)  Diagnostics  Term Loan (11.00% cash (Libor + 10.50%; Floor   3,000    2,945    2,945 
      11.00%; Ceiling 12.50%), 3.00% ETP, Due 1/1/18)               
Radisphere National Radiology Group, Inc. (2)    Diagnostics  Revolver (11.25% cash (Prime + 8.00%), Due 10/1/15)   12,000    11,948    11,948 
Watermark Medical, Inc. (2)  Other Healthcare  Term Loan (12.00% cash, 4.00% ETP, Due 4/1/17)   3,500    3,467    3,467 
      Term Loan (12.00% cash, 4.00% ETP, Due 4/1/17)   3,500    3,467    3,467 
Recondo Technology, Inc. (2)  Software  Term Loan (11.50% cash, 4.14% ETP, Due 4/1/16)   1,384    1,369    1,369 
      Term Loan (11.00% cash, 3.00% ETP, Due 1/1/17)   2,500    2,483    2,483 
      Term Loan (10.50% cash, 2.50% ETP, Due 1/1/18)   2,500    2,476    2,476 
Total Debt Investments — Healthcare information and services              28,155    28,155 
Total Debt Investments              195,956    195,651 
Warrant Investments — 4.1% (9)               
Warrants — Life Science — 1.0% (9)               
ACT Biotech Corporation  Biotechnology  1,521,820 Preferred Stock Warrants       83     
Ambit Biosciences, Inc.(5)  Biotechnology  44,795 Common Stock Warrants       143     
Argos Therapeutics, Inc.(5)  Biotechnology  16,556 Common Stock Warrants       33    33 
Celsion Corporation (5)  Biotechnology  5,708 Common Stock Warrants       15     
Inotek Pharmaceuticals Corporation  Biotechnology  114,387 Preferred Stock Warrants       17    16 
N30 Pharmaceuticals, Inc.  Biotechnology  53,550 Common Stock Warrants       122     
New Haven Pharmaceuticals, Inc.  Biotechnology  41,482 Preferred Stock Warrants       27    123 
Revance Therapeutics, Inc. (5)  Biotechnology  34,377 Common Stock Warrants       68    189 

 

See Notes to Consolidated Financial Statements

 

8
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments (Unaudited)

September 30, 2014

(In thousands)

 

         Principal   Cost of   Fair 
Portfolio Company (1)  Sector  Type of Investment (3)(4)(7)(10)(11)  Amount   Investments (6)   Value 
Sample6, Inc.  Biotechnology  351,018 Preferred Stock Warrants       45    40 
Sunesis Pharmaceuticals, Inc. (5)  Biotechnology  116,203 Common Stock Warrants       83    582 
Supernus Pharmaceuticals, Inc. (2)(5)  Biotechnology  42,083 Preferred Stock Warrants       93    181 
Tranzyme, Inc. (5)  Biotechnology  6,460 Common Stock Warrants       6     
Accuvein, Inc.  Medical Device  58,284 Preferred Stock Warrants       18    23 
Direct Flow Medical, Inc.  Medical Device  176,922 Preferred Stock Warrants       144    113 
EnteroMedics, Inc. (5)  Medical Device  141,026 Common Stock Warrants       347     
IntegenX, Inc. (2)  Medical Device  158,006 Preferred Stock Warrants       33    33 
Lantos Technologies, Inc. (2)  Medical Device  858,545 Preferred Stock Warrants       24    24 
Mederi Therapeutics, Inc. (2)  Medical Device  248,736 Preferred Stock Warrants       26    42 
Mitralign, Inc.  Medical Device  295,238 Preferred Stock Warrants       52    4 
OraMetrix, Inc. (2)  Medical Device  812,348 Preferred Stock Warrants       78     
Tengion, Inc. (2)(5)  Medical Device  1,864,876 Common Stock Warrants       123     
Tryton Medical, Inc.  Medical Device  122,362 Preferred Stock Warrants       15    14 
ViOptix, Inc.  Medical Device  375,763 Preferred Stock Warrants       13     
Zetroz  Medical Device  475,561 Preferred Stock Warrants       25    25 
Total Warrants — Life Science              1,633    1,442 
Warrants — Technology — 2.5% (9)               
Ekahau, Inc. (2)  Communications  978,261 Preferred Stock Warrants       33    25 
OpenPeak, Inc.  Communications  18,997 Common Stock Warrants       89     
Overture Networks, Inc.  Communications  344,574 Preferred Stock Warrants       55    1 
Everyday Health, Inc. (5)  Consumer-related Technologies  43,783 Common Stock Warrants       69    153 
Gwynnie Bee, Inc. (2)  Consumer-related Technologies  268,591 Preferred Stock Warrants       68    190 
SnagAJob.com, Inc.  Consumer-related Technologies  365,396 Preferred Stock Warrants       23    305 
Tagged, Inc.  Consumer-related Technologies  190,868 Preferred Stock Warrants       26    71 
XIOtech, Inc.  Data Storage  2,217,979 Preferred Stock Warrants       21    19 
Cartera Commerce, Inc.  Internet and media  90,909 Preferred Stock Warrants       16    159 
Optaros, Inc.  Internet and media  477,403 Preferred Stock Warrants       21     
SimpleTuition, Inc.  Internet and media  189,573 Preferred Stock Warrants       63    31 
IntelePeer, Inc.  Networking  141,549 Preferred Stock Warrants       39    35 
Nanocomp Technologies, Inc. (2)  Networking  204,546 Preferred Stock Warrants       19    19 
Aquion Energy, Inc.  Power Management  115,051 Preferred Stock Warrants       7    58 
Avalanche Technology, Inc.  Semiconductors  244,649 Preferred Stock Warrants       56    56 
eASIC Corporation  Semiconductors  40,445 Preferred Stock Warrants       25    24 
InVisage Technologies, Inc. (2)  Semiconductors  165,147 Preferred Stock Warrants       43    43 
Kaminario, Inc.  Semiconductors  1,087,203 Preferred Stock Warrants       59    56 
Luxtera, Inc.  Semiconductors  2,087,766 Preferred Stock Warrants       42    114 
NexPlanar Corporation  Semiconductors  216,001 Preferred Stock Warrants       36    57 
Soraa, Inc. (2)  Semiconductors  180,000 Preferred Stock Warrants       80    81 
Xtera Communications, Inc.  Semiconductors  983,607 Preferred Stock Warrants       206     
Bolt Solutions, Inc.  Software  202,892 Preferred Stock Warrants       113    124 
Clarabridge, Inc.  Software  53,486 Preferred Stock Warrants       14    105 
Construction Software Technologies, Inc.  Software  386,415 Preferred Stock Warrants       69    512 
Courion Corporation  Software  772,543 Preferred Stock Warrants       107    91 
Decisyon, Inc.  Software  457,876 Preferred Stock Warrants       46    11 
DriveCam, Inc.  Software  71,639 Preferred Stock Warrants       20    121 
Lotame Solutions, Inc.  Software  288,115 Preferred Stock Warrants       22    161 
Netuitive, Inc.  Software  41,569 Preferred Stock Warrants       48     
Raydiance, Inc.  Software  1,051,120 Preferred Stock Warrants       71    70 
Razorsight Corporation (2)  Software  259,404 Preferred Stock Warrants       43    45 
Riv Data Corp. (2)  Software  237,361 Preferred Stock Warrants       13    13 
SpringCM, Inc. (2)  Software  2,385,686 Preferred Stock Warrants       55    56 
Sys-Tech Solutions, Inc.  Software  375,000 Preferred Stock Warrants       242    582 
Vidsys, Inc.  Software  37,346 Preferred Stock Warrants       23     
Visage Mobile, Inc.  Software  1,692,047 Preferred Stock Warrants       19    18 
Total Warrants — Technology              2,001    3,406 
Warrants — Cleantech — 0.2% (9)               
Renmatix, Inc.  Alternative Energy  52,296 Preferred Stock Warrants       68    71 
Semprius, Inc.  Alternative Energy  519,981 Preferred Stock Warrants       26     
Rypos, Inc. (2)  Energy Efficiency  5,627 Preferred Stock Warrants       44    42 
Solarbridge Technologies, Inc.  Energy Efficiency  7,381,412 Preferred Stock Warrants       235    168 
Tigo Energy, Inc. (2)  Energy Efficiency  804,604 Preferred Stock Warrants       100    34 
Total Warrants — Cleantech              473    315 

 

See Notes to Consolidated Financial Statements

 

9
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments (Unaudited)

September 30, 2014

(In thousands)

 

         Principal   Cost of   Fair 
Portfolio Company (1)  Sector  Type of Investment (3)(4)(7)(10)(11)  Amount   Investments (6)   Value 
Warrants — Healthcare information and services — 0.4% (9)                
Accumetrics, Inc.  Diagnostics  100,928 Preferred Stock Warrants       107    63 
BioScale, Inc. (2)  Diagnostics  315,618 Preferred Stock Warrants       54     
LifePrint Group, Inc. (2)  Diagnostics  49,000 Preferred Stock Warrants       29    29 
Precision Therapeutics, Inc.  Diagnostics  13,461 Preferred Stock Warrants       73     
Radisphere National Radiology Group, Inc. (2)  Diagnostics  519,992 Preferred Stock Warrants       378     
Singulex, Inc.  Other Healthcare  293,632 Preferred Stock Warrants       44    143 
Talyst, Inc.  Other Healthcare  300,360 Preferred Stock Warrants       101    54 
Watermark Medical, Inc.  Other Healthcare  12,216 Preferred Stock Warrants       67    65 
Recondo Technology, Inc. (2)  Software  436,088 Preferred Stock Warrants       73    177 
 Total Warrants — Healthcare information and services              926    531 
Total Warrants              5,033    5,694 
                      
Other Investments — 0.2% (9)                     
Vette Technology, LLC  Data Storage  Royalty Agreement Due 4/18/2019       4,645    300 
Total Other Investments              4,645    300 
Equity — 2.2% (9)                     
Insmed Incorporated (5)  Biotechnology  33,208 Common Stock       239    433 
Revance Therapeutics, Inc.(5)  Biotechnology  4,861 Common Stock       72    94 
Overture Networks Inc.  Communications  386,191 Common Stock       482    222 
Solarbridge Technologies, Inc.  Energy Efficiency  11,716,760 Preferred Stock       2,300    2,300 
Total Equity              3,093    3,049 
Total Portfolio Investment Assets — 147.8%  (9)       $208,727   $204,694 
Short Term Investments — Money Market Funds — 0.6% (9)                
US Bank Money Market Deposit Account       $800   $800 
Total Short Term Investments — Money Market Funds       $800   $800 
Short Term Investments — Restricted  Investments— 2.4% (9)                  
US Bank Money Market Deposit Account (2)       $3,368   $3,368 
Total Short Term Investments — Restricted  Investments       $3,368   $3,368 

_____________________________

 

(1)   All of the Company’s investments are in entities which are organized under the laws of the United States and have a principal place of business in the United States.
(2)   Has been pledged as collateral under the Key Facility or 2013-1 Securitization.
(3)   All investments are less than 5% ownership of the class and ownership of the portfolio company.
(4)   All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not include ETP and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. All debt investments are at fixed rates for the term of the loan, unless otherwise indicated. For each debt investment, the current interest rate in effect as of September 30, 2014 is provided.
(5)   Portfolio company is a public company.
(6)   For debt investments, represents principal balance less unearned income.
(7)   Preferred and common stock warrants, equity interests and other investments are non-income producing.
(8)   Debt is on non-accrual status at September 30, 2014 and is, therefore, considered non-income producing.
(9)   Value as a percent of net assets.
(10)   The Company did not have any non-qualifying assets under Section 55(a) of the 1940 Act. Under the 1940 Act, the Company may not acquire any non-qualifying assets unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company’s total assets.
(11)  

ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable loan, including upon any prepayment, and are a fixed percentage of the original principal balance of the loan unless otherwise noted. Interest will accrue during the life of the loan on each end-of-term payment and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee will be based on income that the Company has not yet received in cash.

 

See Notes to Consolidated Financial Statements

 

10
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments (Unaudited)

December 31, 2013

(In thousands)

 

         Principal   Cost of   Fair 
Portfolio Company (1)  Sector  Type of Investment (3)(4)(7)(10)(11)  Amount   Investments (6)   Value 
Debt Investments — 157.5% (9)               
Debt Investments — Life Science — 22.9% (9)               
Inotek Pharmaceuticals Corporation (2)  Biotechnology  Term Loan (11.00% cash, 3.00% ETP, Due 10/1/16)  $3,500   $3,460   $3,460 
N30 Pharmaceuticals, Inc. (2)   Biotechnology  Term Loan (11.25% cash, 3.00% ETP, Due 9/1/14)   760    756    756 
      Term Loan (11.25% cash, 3.00% ETP, Due 10/1/15)   2,230    2,209    2,209 
New Haven Pharmaceuticals, Inc. (2)  Biotechnology  Term Loan (11.50% cash, 3.00% ETP, Due 5/1/16)   1,500    1,476    1,476 
      Term Loan (11.50% cash, 3.00% ETP, Due 5/1/16)   500    492    492 
Sample6, Inc. (2)  Biotechnology  Term Loan (11.00% cash, 3.00% ETP, Due 1/1/16)   2,252    2,229    2,229 
Sunesis Pharmaceuticals, Inc. (2)(5)   Biotechnology  Term Loan (8.95% cash, 3.75% ETP, Due 10/1/15)   1,425    1,418    1,418 
      Term Loan (9.00% cash, 3.75% ETP, Due 10/1/15)   2,138    2,100    2,100 
Xcovery Holding Company, LLC (2)   Biotechnology  Term Loan (12.50% cash, Due 8/1/15)   781    779    779 
      Term Loan (12.50% cash, Due 8/1/15)   1,228    1,226    1,226 
      Term Loan (12.50% cash, Due 10/1/15)   231    231    231 
Mederi Therapeutics, Inc.  Medical Device  Term Loan (10.75% cash (Libor + 10.25%; Floor   3,000    2,957    2,957 
      10.75%; Ceiling 12.75%), 4.00% ETP, Due 7/1/17)               
      Term Loan (10.75% cash (Libor + 10.25%; Floor   3,000    2,917    2,917 
      10.75%; Ceiling 12.75%), 4.00% ETP, Due 7/1/17)               
Mitralign, Inc. (2)  Medical Device  Term Loan (12.00% cash, 3.00% ETP, Due 10/1/15)   1,587    1,571    1,571 
      Term Loan (10.88% cash, 3.00% ETP, Due 11/1/15)   1,100    1,089    1,089 
      Term Loan (10.50% cash, 3.00% ETP, Due 7/1/16)   1,143    1,115    1,115 
PixelOptics, Inc. (8)   Medical Device  Term Loan (10.75% cash, 3.00% ETP, Due 11/1/14)   5,000    4,985    562 
      Term Loan (10.00% cash, Due 1/31/14)   219    219    219 
Tengion, Inc. (2)(5)   Medical Device  Term Loan (13.00% cash, Due 5/1/14)   1,382    1,373    1,373 
Tryton Medical, Inc. (2)  Medical Device  Term Loan (10.41% cash (Prime + 7.16%), 2.50% ETP, Due 9/1/16)   3,000    2,962    2,962 
Total Debt Investments — Life Science              35,564    31,141 
Debt Investments — Technology — 98.3% (9)               
Ekahau, Inc.  Communications  Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17)   1,500    1,474    1,474 
      Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17)   500    490    490 
Overture Networks, Inc. (2)  Communications  Term Loan (10.75% cash, 4.75% ETP, Due 12/1/16)   5,000    4,935    4,935 
      Term Loan (10.75% cash, 4.75% ETP, Due 12/1/16)   2,500    2,460    2,460 
Optaros, Inc. (2)   Internet and Media  Term Loan (11.95% cash, 3.00% ETP, Due 10/1/15)   1,670    1,660    1,660 
      Term Loan (11.95% cash, 3.00% ETP, Due 3/1/16)   500    497    497 
SimpleTuition, Inc. (2)  Internet and Media  Term Loan (11.75% cash, Due 3/1/16)   3,909    3,862    3,862 
Nanocomp Technologies, Inc.  Networking  Term Loan (11.50% cash, 3.00% ETP, Due 11/1/17)   1,000    963    963 
Aquion Energy, Inc. (2)  Power Management  Term Loan (10.25% cash, 4.00% ETP, Due 3/1/16)   2,704    2,693    2,693 
      Term Loan (10.25% cash, 4.00% ETP, Due 3/1/16)   2,704    2,693    2,693 
      Term Loan (10.25% cash, 4.00% ETP, Due 6/1/16)   2,978    2,966    2,966 
Xtreme Power, Inc. (2)(8)  Power Management  Term Loan (10.75% cash, 9.00% ETP, Due 5/1/16)   6,000    5,947    4,692 
Avalanche Technology, Inc. (2)  Semiconductors  Term Loan (10.00% cash, 2.00% ETP, Due 7/1/16)   2,996    2,973    2,973 
      Term Loan (10.00% cash, 2.00% ETP, Due 1/1/18)   2,500    2,455    2,455 
eASIC Corporation (2)  Semiconductors  Term Loan (11.00% cash, 2.50% ETP, Due  4/1/17)   2,000    1,968    1,968 
Kaminario, Inc. (2)  Semiconductors  Term Loan (10.50% cash, 2.50% ETP, Due 11/1/16)   3,000    2,954    2,954 
      Term Loan (10.50% cash, 2.50% ETP, Due 11/1/16)   3,000    2,954    2,954 
Luxtera, Inc. (2)  Semiconductors  Term Loan (10.25% cash, 8.00% ETP, Due 12/1/15)   2,734    2,714    2,714 
      Term Loan (10.25% cash, 8.00% ETP, Due 3/1/16)   1,519    1,506    1,506 
Newport Media, Inc. (2)  Semiconductors  Term Loan (11.00% cash, 2.86% ETP, Due 10/1/16)   3,500    3,418    3,418 
      Term Loan (11.00% cash, 2.86% ETP, Due 10/1/16)   3,500    3,418    3,418 
NexPlanar Corporation (2)  Semiconductors  Term Loan (10.50% cash, 2.50% ETP, Due 12/1/16)   3,000    2,964    2,964 
      Term Loan (10.50% cash, 2.50% ETP, Due 12/1/16)   2,000    1,967    1,967 
Xtera Communications, Inc. (2)   Semiconductors  Term Loan (11.50% cash, 14.77% ETP, Due 7/1/15)   6,468    6,441    6,441 
      Term Loan (11.50% cash, 13.65% ETP, Due 2/1/16)   1,731    1,718    1,718 
Bolt Solutions, Inc. (2)   Software  Term Loan (11.65% cash, 4.00% ETP, Due 5/1/16)   4,856    4,819    4,819 
      Term Loan (11.65% cash, 4.00% ETP, Due 5/1/16)   4,856    4,819    4,819 
Construction Software Technologies, Inc. (2)   Software  Term Loan (11.75% cash, 5.00% ETP, Due 10/1/16)   4,200    4,172    4,172 
      Term Loan (11.75% cash, 5.00% ETP, Due 10/1/16)   4,200    4,172    4,172 
Courion Corporation (2)   Software  Term Loan (11.45% cash, Due 10/1/15)   2,662    2,654    2,654 
      Term Loan (11.45% cash, Due 10/1/15)   2,662    2,654    2,654 
Decisyon, Inc. (2)  Software  Term Loan (11.65% cash, 5.00% ETP, Due 9/1/16)   4,000    3,932    3,932 
Kontera Technologies, Inc. (2)  Software  Term Loan (11.50% cash, 3.00% ETP, Due 10/1/16)   4,000    3,949    3,949 
      Term Loan (11.50% cash, 3.00% ETP, Due 10/1/16)   4,000    3,949    3,949 

 

See Notes to Consolidated Financial Statements

 

11
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments (Unaudited)

December 31, 2013

(In thousands)

 

         Principal   Cost of   Fair 
Portfolio Company (1)  Sector  Type of Investment (3)(4)(7)(10)(11)  Amount   Investments (6)   Value 
Lotame Solutions, Inc. (2)  Software  Term Loan (11.50% cash, 3.00% ETP, Due 10/1/16)   4,000    3,971    3,971 
      Term Loan (11.50% cash, 3.00% ETP, Due 9/1/16)   1,500    1,486    1,486 
Netuitive, Inc. (2)  Software  Term Loan (11.75% cash, Due 1/1/16)   2,359    2,330    2,330 
Raydiance, Inc. (2)  Software  Term Loan (11.50% cash, 2.75% ETP, Due 9/1/16)   5,000    4,948    4,948 
      Term Loan (11.50% cash, 2.75% ETP, Due 9/1/16)   1,000    975    975 
Razorsight Corporation (2)  Software  Term Loan (11.75% cash, 3.00% ETP, Due 11/1/16)   1,500    1,477    1,477 
      Term Loan (11.75% cash, 3.00% ETP, Due 8/1/16)   1,500    1,475    1,475 
   Software  Term Loan (11.75% cash, 3.00% ETP, Due 7/1/17)   1,000    980    980 
Sys-Tech Solutions, Inc. (2)  Software  Term Loan (11.65% cash, Due 6/1/16)   7,100    6,919    6,919 
VBrick Systems, Inc.  Software  Term Loan (11.50% cash (Libor + 10.00%; Floor   3,000    2,970    2,970 
      10.50%; Ceiling 13.50%), 5.00% ETP, Due 7/1/17)               
Vidsys, Inc. (2)  Software  Term Loan (11.00% cash, 6.50% ETP, Due 6/1/16)   3,000    2,970    2,970 
Visage Mobile, Inc. (2)  Software  Term Loan (12.00% cash, 3.50% ETP, Due 9/1/16)   974    962    962 
Total Debt Investments — Technology               134,673    133,418 
Debt Investments — Cleantech — 17.6% (9)               
Renmatix, Inc. (2)  Alternative Energy  Term Loan (10.25% cash, 9.00% ETP, Due 2/1/16)   2,028    2,015    2,015 
      Term Loan (10.25% cash, 3.00% ETP, Due 2/1/16)   2,028    2,015    2,015 
      Term Loan (10.25% cash, Due 10/1/16)   5,000    4,956    4,956 
Semprius, Inc. (2)(8)  Alternative Energy  Term Loan (10.25% cash, 2.50% ETP, Due 6/1/16)   3,203    3,183    2,785 
Aurora Algae, Inc. (2)  Energy Efficiency  Term Loan (10.50% cash, 2.00% ETP, Due 5/1/15)   1,280    1,276    1,276 
Rypos, Inc.  Energy Efficiency  Term Loan (11.80% cash, Due 1/1/17)   3,000    2,928    2,928 
Solarbridge Technologies, Inc. (2)(8)  Energy Efficiency  Term Loan (12.15% cash, 3.21% ETP, Due 12/1/16)   7,000    6,785    5,000 
Tigo Energy, Inc.  (2)  Energy Efficiency  Term Loan (13.00% cash, 3.16% ETP,  Due 6/1/15)   2,214    2,199    2,199 
Cereplast, Inc. (5)(8)  Waste Recycling  Term Loan (12.00% cash, Due 8/1/14)   1,081    978    328 
      Term Loan (12.00% cash, Due 8/1/14)   1,160    1,141    352 
Total Debt Investments — Cleantech              27,476    23,854 
Debt Investments — Healthcare information and services — 18.7% (9)                
BioScale, Inc. (2)  Diagnostics  Term Loan (11.51% cash, Due 1/1/14)   232    232    232 
Radisphere National Radiology Group, Inc. (2)  Diagnostics  Revolver (11.25% cash (Prime + 8.00%), Due 10/1/15)   12,000    11,908    11,908 
Watermark Medical, Inc. (2)  Other Healthcare  Term Loan (12.00% cash, 4.00% ETP, Due 4/1/17)   3,500    3,452    3,452 
      Term Loan (12.00% cash, 4.00% ETP, Due 4/1/17)   3,500    3,452    3,452 
Recondo Technology, Inc. (2)  Software  Term Loan (11.50% cash, 4.14% ETP, Due 4/1/16)   1,384    1,356    1,356 
      Term Loan (11.00% cash, 3.00% ETP, Due 1/1/17)   2,500    2,473    2,473 
   Other Healthcare  Term Loan (10.50% cash, 2.50% ETP, Due 1/1/18)   2,500    2,468    2,468 
Total Debt Investments — Healthcare information and services              25,341    25,341 
Total Debt Investments              223,054    213,754 
Warrant Investments — 4.5% (9)               
Warrants — Life Science — 2.1% (9)               
ACT Biotech Corporation  Biotechnology  1,521,820 Preferred Stock Warrants       83     
Ambit Biosciences, Inc.(5)  Biotechnology  44,795 Common Stock Warrants       143    9 
Anacor Pharmaceuticals, Inc. (2)(5)  Biotechnology  84,583 Common Stock Warrants       93    882 
Celsion Corporation (5)  Biotechnology  5,708 Common Stock Warrants       15     
Inotek Pharmaceuticals Corporation  Biotechnology  114,387 Preferred Stock Warrants       17    15 
N30 Pharmaceuticals, Inc.  Biotechnology  214,200 Preferred Stock Warrants       122    247 
New Haven Pharmaceuticals, Inc.  Biotechnology  34,729 Preferred Stock Warrants       22    20 
Revance Therapeutics, Inc.  Biotechnology  687,091 Preferred Stock Warrants       223    945 
Sample6, Inc.  Biotechnology  200,582 Preferred Stock Warrants       27    23 
Sunesis Pharmaceuticals, Inc. (5)  Biotechnology  116,203 Common Stock Warrants       83    308 
Supernus Pharmaceuticals, Inc. (2)(5)  Biotechnology  42,083 Preferred Stock Warrants       94    132 
Tranzyme, Inc. (5)  Biotechnology  77,902 Common Stock Warrants       6     
Direct Flow Medical, Inc.  Medical Device  176,922 Preferred Stock Warrants       144    132 
EnteroMedics, Inc. (5)  Medical Device  141,026 Common Stock Warrants       347     
Mederi Therapeutics, Inc.  Medical Device  248,736 Preferred Stock Warrants       26    26 
Mitralign, Inc.  Medical Device  295,238 Common Stock Warrants       49    35 
OraMetrix, Inc. (2)  Medical Device  812,348 Preferred Stock Warrants       78     
PixelOptics, Inc.  Medical Device  381,612 Preferred Stock Warrants       96     
Tengion, Inc. (2)(5)  Medical Device  1,864,876 Common Stock Warrants       124     
Tryton Medical, Inc. (2)  Medical Device  47,977 Preferred Stock Warrants       14    14 
ViOptix, Inc.  Medical Device  375,763 Preferred Stock Warrants       13     
Total Warrants — Life Science              1,819    2,788 

 

See Notes to Consolidated Financial Statements

 

12
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments (Unaudited)

December 31, 2013

(In thousands)

 

         Principal   Cost of   Fair 
Portfolio Company (1)  Sector  Type of Investment (3)(4)(7)(10)(11)  Amount   Investments (6)   Value 
Warrants — Technology — 1.8% (9)               
Ekahau, Inc.  Communications  978,261 Preferred Stock Warrants       34    26 
OpenPeak, Inc.  Communications  18,997 Preferred Stock Warrants       89     
Overture Networks, Inc.  Communications  344,574 Preferred Stock Warrants       55    42 
Everyday Health, Inc.  Consumer-related Technologies  65,674 Preferred Stock Warrants       69    94 
SnagAJob.com, Inc.  Consumer-related Technologies  365,396 Preferred Stock Warrants       23    269 
Tagged, Inc.  Consumer-related Technologies  190,868 Preferred Stock Warrants       26    72 
XIOtech, Inc.  Data Storage  2,217,979 Preferred Stock Warrants       22    19 
Cartera Commerce, Inc.  Internet and media  90,909 Preferred Stock Warrants       16    160 
Optaros, Inc.  Internet and media  477,403 Preferred Stock Warrants       21    13 
SimpleTuition, Inc.  Internet and media  189,573 Preferred Stock Warrants       63    9 
IntelePeer, Inc.  Networking  141,549 Preferred Stock Warrants       39    34 
Motion Computing, Inc.  Networking  104,283 Preferred Stock Warrants       4    18 
Nanocomp Technologies, Inc.  Networking  204,546 Preferred Stock Warrants       19    19 
Aquion Energy, Inc.  Power Management  115,051 Preferred Stock Warrants       8    57 
Xtreme Power, Inc.  Power Management  2,466,821 Preferred Stock Warrants       76     
Avalanche Technology, Inc.  Semiconductors  244,649 Preferred Stock Warrants       56    66 
eASIC Corporation`  Semiconductors  1,877,799 Preferred Stock Warrants       16    15 
Kaminario, Inc.  Semiconductors  1,087,203 Preferred Stock Warrants       59    54 
Luxtera, Inc.  Semiconductors  1,827,485 Preferred Stock Warrants       34    105 
Newport Media, Inc.  Semiconductors  188,764 Preferred Stock Warrants       40    47 
NexPlanar Corporation  Semiconductors  216,001 Preferred Stock Warrants       36    56 
Xtera Communications, Inc.  Semiconductors  983,607 Preferred Stock Warrants       206     
Bolt Solutions, Inc.  Software  202,892 Preferred Stock Warrants       113    124 
Clarabridge, Inc.  Software  53,486 Preferred Stock Warrants       14    104 
Construction Software Technologies, Inc. (2)  Software  386,415 Preferred Stock Warrants       69    335 
Courion Corporation  Software  772,543 Preferred Stock Warrants       106    89 
Decisyon, Inc.  Software  314,686 Preferred Stock Warrants       44    39 
DriveCam, Inc.  Software  71,639 Preferred Stock Warrants       20    120 
Kontera Technologies, Inc. (2)  Software  99,476 Preferred Stock Warrants       102    82 
Lotame Solutions, Inc.  Software  216,810 Preferred Stock Warrants       4    3 
Netuitive, Inc.  Software  748,453 Preferred Stock Warrants       75    45 
Raydiance, Inc.  Software  735,784 Preferred Stock Warrants       51    48 
Razorsight Corporation  Software  259,404 Preferred Stock Warrants       44    40 
Sys-Tech Solutions, Inc.  Software  375,000 Preferred Stock Warrants       242    239 
Vidsys, Inc.  Software  37,346 Preferred Stock Warrants       23     
Visage Mobile, Inc.  Software  1,692,047 Preferred Stock Warrants       20    18 
Total Warrants — Technology              1,938    2,461 
Warrants — Cleantech — 0.2% (9)               
Renmatix, Inc.  Alternative Energy  52,296 Preferred Stock Warrants       68    69 
Semprius, Inc.  Alternative Energy  519,981 Preferred Stock Warrants       26     
Enphase Energy, Inc. (5)  Energy Efficiency  161,959 Common Stock Warrants       175    126 
Rypos, Inc.  Energy Efficiency  5,627 Preferred Stock Warrants       44    41 
Solarbridge Technologies, Inc. (2)  Energy Efficiency  3,645,302 Preferred Stock Warrants       236     
Tigo Energy, Inc. (2)  Energy Efficiency  804,604 Preferred Stock Warrants       100    26 
Cereplast, Inc. (5)  Waste Recycling  365,000 Common Stock Warrants       175     
Total Warrants — Cleantech              824    262 
Warrants — Healthcare information and services — 0.4% (9)            
Accumetrics, Inc.  Diagnostics  100,928 Preferred Stock Warrants       107    63 
BioScale, Inc. (2)  Diagnostics  315,618 Preferred Stock Warrants       54     
Precision Therapeutics, Inc.  Diagnostics  13,461 Preferred Stock Warrants       73     
Radisphere National Radiology Group, Inc. (2)  Diagnostics  519,992 Preferred Stock Warrants       378     
Patientkeeper, Inc.  Other Healthcare  396,410 Preferred Stock Warrants       269    29 
Singulex, Inc.  Other Healthcare  293,632 Preferred Stock Warrants       44    140 
Talyst, Inc.  Other Healthcare  300,360 Preferred Stock Warrants       100    53 
Watermark Medical, Inc.  Other Healthcare  12,216 Preferred Stock Warrants       66    64 
Recondo Technology, Inc.  Software  436,088 Preferred Stock Warrants       73    176 
Total Warrants — Healthcare information and services              1,164    525 
Total Warrants              5,745    6,036 

 

See Notes to Consolidated Financial Statements

 

13
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Consolidated Schedule of Investments (Unaudited)

December 31, 2013

(In thousands)

 

         Principal   Cost of   Fair 
Portfolio Company (1)  Sector  Type of Investment (3)(4)(7)(10)(11)  Amount   Investments (6)   Value 
Other Investments — 0.3% (9)                     
Vette Technology, LLC  Data Storage  Royalty Agreement Due 4/18/2019       4,729    400 
Total Other Investments              4,729    400 
Equity — 0.8% (9)                     
Insmed Incorporated (5)  Biotechnology  33,208 Common Stock       227    565 
Revance Therapeutics, Inc.  Biotechnology  72,925 Preferred Stock       73    109 
Overture Networks Inc.  Communications  386,191 Common Stock       482    420 
Cereplast, Inc. (5)  Waste Recycling  200,000 Common Stock            
Total Equity              782    1,094 
Total Portfolio Investment Assets — 163.1%  (9)       $234,310   $221,284 
Short Term Investments — Money Market Funds — 0.9% (9)                
US Bank Money Market Deposit Account       $1,188   $1,188 
Total Short Term Investments — Money Market Funds       1,188   $1,188 
Short Term Investments — Restricted  Investments— 4.4% (9)                  
US Bank Money Market Deposit Account (2)       $5,951   $5,951 
Total Short Term Investments — Restricted  Investments       $5,951   $5,951 

_____________________________

 

(1)   All of the Company’s investments are in entities which are organized under the laws of the United States and have a principal place of business in the United States.
(2)   Has been pledged as collateral under the Credit Facilities or 2013-1 Securitization.
(3)   All investments are less than 5% ownership of the class and ownership of the portfolio company.
(4)   All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not include ETP and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. All debt investments are at fixed rates for the term of the loan, unless otherwise indicated. For each debt investment, the current interest rate in effect as of December 31, 2013 is provided.
(5)   Portfolio company is a public company.
(6)   For debt investments, represents principal balance less unearned income.
(7)   Preferred and common stock warrants, equity interests and other investments are non-income producing.
(8)   Debt is on non-accrual status at December 31, 2013 and is, therefore, considered non-income producing.
(9)   Value as a percent of net assets.
(10)   The Company did not have any non-qualifying assets under Section 55(a) of the 1940 Act. Under the 1940 Act, the Company may not acquire any non-qualifying assets unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company’s total assets.
(11)  

ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable loan, including upon any prepayment, and are a fixed percentage of the original principal balance of the loan unless otherwise noted. Interest will accrue during the life of the loan on each end-of-term payment and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee will be based on income that the Company has not yet received in cash. 

 

See Notes to Consolidated Financial Statements

 

14
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

 

Note 1.  Organization

 

Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 and is an externally managed, non-diversified, closed-end investment company. The Company has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). In addition, for tax purposes, the Company has elected to be treated as a regulated investment company (“RIC”) as defined under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company generally is not subject to corporate-level federal income tax on the portion of its taxable income and capital gains the Company distributes to its stockholders. The Company primarily makes secured loans to development-stage companies in the technology, life science, healthcare information and services and cleantech industries. All of the Company’s debt investments consist of loans secured by all of, or a portion of, the applicable debtor company’s tangible and intangible assets.

 

On October 28, 2010, the Company completed an initial public offering (“IPO”) and its common stock trades on the NASDAQ Global Select Market under the symbol “HRZN.” The Company was formed to continue and expand the business of Compass Horizon Funding Company LLC (“CHF”), a Delaware limited liability company, which commenced operations in March 2008 and became the Company’s wholly owned subsidiary upon the completion of the IPO.

 

Horizon Credit I LLC (“Credit I”) was formed as a Delaware limited liability company on January 23, 2008, with CHF as its sole equity member. Credit I is a separate legal entity from the Company and CHF. There has been no activity at Credit I during the nine months ended September 30, 2014.

 

Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, with the Company as its sole equity member. Credit II is a special purpose bankruptcy remote entity and is a separate legal entity from the Company. Any assets conveyed to Credit II are not available to creditors of the Company or any other entity other than Credit II’s lenders.

 

Horizon Credit III LLC (“Credit III”) was formed as a Delaware limited liability company on May 30, 2012, with the Company as its sole equity member. Credit III is a special purpose bankruptcy remote entity and is a separate legal entity from the Company. Any assets conveyed to Credit III are not available to creditors of the Company or any other entity other than Credit III’s lenders.

 

Longview SBIC GP LLC and Longview SBIC LP (collectively, “Horizon SBIC”) were formed as a Delaware limited liability company and Delaware limited partnership, respectively, on February 11, 2011. Horizon SBIC are wholly owned subsidiaries of the Company and were formed in anticipation of obtaining a license to operate a small business investment company from the U. S. Small Business Administration (“SBA”). There has been no activity in Horizon SBIC since its inception.

 

The Company formed Horizon Funding 2013-1 LLC (“2013-1 LLC”) as a Delaware limited liability company on June 7, 2013 and Horizon Funding Trust 2013-1 (“2013-1 Trust” and, together with 2013-1 LLC, the “2013-1 Entities”) as a Delaware trust on June 18, 2013. The 2013-1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2013-1 Entities for purposes of securitizing $189.3 million of secured loans and issuing fixed-rate asset-backed notes in an aggregate principal amount of $90 million (the “Asset-Backed Notes”).

 

The Company has also established wholly owned subsidiaries, each of which is structured as a Delaware limited liability company, to hold portfolio companies assets acquired in connection with foreclosure or bankruptcy. Each is a separate legal entity from the Company.

 

The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an amended and restated investment management agreement (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (“HTFM” or the “Advisor”), under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company.

 

15
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

 

Note 2.  Basis of Presentation and Significant Accounting Policies

 

The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10-Q and Article 6 or 10 of Regulation S-X. In the opinion of management, the consolidated financial statements reflect all adjustments and reclassifications that are necessary for the fair presentation of financial results as of and for the periods presented. All intercompany balances and transactions have been eliminated. Certain prior period amounts have been reclassified to conform to the current period presentation. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the year. Therefore, the unaudited financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2013.

 

Principles of Consolidation

 

As required under GAAP and Regulation S-X, the Company will generally consolidate its investment in a company that is an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Accordingly, the Company consolidated the results of the Company’s subsidiaries in its consolidated financial statements.

 

Use of Estimates

 

In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.

 

Fair Value

 

The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy as more fully described in Note 5. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date.

 

The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3.

 

See Note 5 for additional information regarding fair value.

 

Segments

 

The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and cleantech industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these loan and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.

 

16
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

 

Investments

 

Investments are recorded at fair value. The Company’s board of directors (“Board”) determines the fair value of its portfolio investments. The Company has the intent to hold its debt investments for the foreseeable future or until maturity or payoff.

 

Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if the Company otherwise does not expect to receive interest and principal repayments, the debt investments is placed on non-accrual status and the recognition of interest income is discontinued. Interest payments received on debt investments that are on non-accrual status are treated as reductions of principal until the principal is repaid or until principal and interest payments are determined to be fully collectible. As of September 30, 2014, there was one debt investment on non-accrual status with a cost basis of $2.6 million and a fair value of $2.3 million. As of December 31, 2013, there were five debt investments on non-accrual status with an aggregate cost of $23.2 million and an aggregate fair value of $13.9 million.

 

The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may also receive a non-refundable deposit earned upon the termination of a transaction. Loan origination fees, net of certain direct origination costs, are deferred, and along with unearned income, are amortized as a level yield adjustment over the respective term of the debt investments. All other income is recognized when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status.

 

Certain loan agreements also require the borrower to make an end-of-term payment (“ETP”) that is accrued into interest income over the life of the debt investments to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not expect the borrower to be able to pay all principal and interest due.

 

In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are also recorded as unearned loan income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized gain or loss on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments.

 

Realized gains or losses on the sale of investments, or upon the determination that an investment balance or portion thereof is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation, when gains or losses are realized.

 

Debt Issuance Costs

 

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. Debt issuance costs are recognized as assets and are amortized as interest expense over the term of the related debt financing. The unamortized balance of debt issuance costs as of September 30, 2014 and December 31, 2013, included in other assets, was $2.7 million and $5.1 million, respectively. The accumulated amortization balances as of September 30, 2014 and December 31, 2013 were $2.7 million and $2.0 million, respectively. The amortization expense for the nine months ended September 30, 2014 and 2013 was $2.4 million and $0.9 million, respectively.

 

17
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

 

Income Taxes

 

As a BDC, the Company has elected to be treated as a RIC under subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute to its stockholders at least 90% of investment company taxable income, as defined by the Code, for each tax year. The Company, among other things, has made and intends to continue to make the requisite distributions to its stockholders, which will generally relieve the Company from corporate-level U.S. federal income taxes.

 

Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year dividend distributions into the next tax year and pay a 4% excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year dividend distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. For both the nine months ended September 30, 2014 and 2013, $0.1 million was recorded for U.S. federal excise tax.

 

The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. The Company had no material uncertain tax positions at September 30, 2014 and December 31, 2013. The 2013, 2012 and 2011 tax years remain subject to examination by U.S. federal and state tax authorities.

 

Distributions

 

Distributions to common stockholders are recorded on the declaration date. The amount to be paid out is determined by the Board. Net realized long-term capital gains, if any, are distributed at least annually, although the Company may decide to retain such capital gains for investment.

 

The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions and other distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board authorizes, and the Company declares, a cash distribution, then stockholders who have not “opted out” of the dividend reinvestment plan will have their cash distributions automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash distribution. The Company may use newly issued shares to implement the plan (especially if the Company’s shares are trading at a premium to net asset value), or the Company may purchase shares in the open market to fulfill its obligations under the plan.

 

Transfers of Financial Assets

 

Assets related to transactions that do not meet Accounting Standards Codification (“ASC”) Topic 860 — Transfers and Servicing requirements for accounting sale treatment are reflected in the Company’s consolidated statements of financial condition as investments. Those assets are owned by special purpose entities that are consolidated in the Company’s financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any affiliate of the Company).

 

Transfers of financial assets are accounted for as sales, when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when (1) the assets have been isolated from the Company — put presumptively beyond the reach of the transferor and its creditors, even in bankruptcy or other receivership, (2) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets, and (3) the transferor does not maintain effective control over the transferred assets through either (a) an agreement that both entitles and obligates the transferor to repurchase or redeem the assets before maturity or (b) the ability to unilaterally cause the holder to return specific assets, other than through a cleanup call.

 

18
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

 

New Accounting Pronouncement

 

In June 2013, FASB issued Accounting Standards Update 2013-08, Financial Services — Investment Companies (Topic 946): Amendments to the Scope, Measurement and Disclosure Requirements, or ASU 2013-08, containing new guidance on assessing whether an entity is an investment company, requiring non-controlling ownership interest in investment companies to be measured at fair value and requiring certain additional disclosures. This guidance is effective for annual and interim periods beginning on or after December 15, 2013. ASU 2013-08 did not have a material impact on the Company’s consolidated financial position or disclosures.

 

Note 3.  Related Party Transactions

 

Investment Management Agreement

 

On October 28, 2010, the Company entered into the Investment Management Agreement with the Advisor, which was amended and restated effective July 1, 2014, under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company. Under the terms of the amended and restated Investment Management Agreement, the Advisor determines the composition of the Company’s investment portfolio, the nature and timing of the changes to the investment portfolio and the manner of implementing such changes; identifies, evaluates and negotiates the structure of the investments the Company makes (including performing due diligence on the Company’s prospective portfolio companies); and closes, monitors and administers the investments the Company makes, including the exercise of any voting or consent rights.

 

The Advisor’s services under the Investment Management Agreement are not exclusive to the Company, and the Advisor is free to furnish similar services to other entities so long as its services to the Company are not impaired. The Advisor is a registered investment adviser with the U.S. Securities and Exchange Commission (the “SEC”). The Advisor receives fees for providing services to the Company under the Investment Management Agreement, consisting of two components, a base management fee and an incentive fee.

 

The base management fee under the Investment Management Agreement through and including June 30, 2014 was calculated at an annual rate of 2.00% of the Company’s gross assets, payable monthly in arrears. As a result of an amendment and restatement of the Investment Management Agreement, the base management fee on and after July 1, 2014 is calculated at an annual rate of 2.00% of (i) the Company’s gross assets, less (ii) assets consisting of cash and cash equivalents, and is payable monthly in arrears. For purposes of calculating the base management fee, the term “gross assets” includes any assets acquired with the proceeds of leverage. During the first six months of the period ended September 30, 2014, the Advisor waived base management fees of $0.2 million, which the Advisor would have otherwise earned on cash held by the Company at the time of calculation. The base management fee payable at both September 30, 2014 and December 31, 2013 was $0.4 million. The base management fee expense was $1.0 million and $1.3 million for the three months ended September 30, 2014 and 2013, respectively. After giving effect of the waiver, the base management fee expense was $3.4 million and $3.8 million for the nine months ended September 30, 2014 and 2013, respectively.

 

The incentive fee has two parts, as follows:

 

The first part which is subject to the Incentive Fee Cap and Deferral Mechanism, as defined below, is calculated and payable quarterly in arrears based on the Company’s pre-incentive fee net investment income for the immediately preceding calendar quarter. For this purpose, pre-incentive fee net investment income means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees received from portfolio companies) accrued during the calendar quarter, minus operating expenses for the quarter (including the base management fee, expenses payable under the administration agreement (as defined below), and any interest expense and any dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-incentive fee net investment income includes, in the case of investments with a deferred interest feature (such as original issue discount, debt instruments with payment-in-kind interest and zero coupon securities), accrued income that the Company has not yet received in cash. The incentive fee with respect to the pre-incentive fee net investment income is 20.00% of the amount, if any, by which the pre-incentive fee net investment income for the immediately preceding calendar quarter exceeds a 1.75% (which is 7.00% annualized) hurdle rate and a “catch-up” provision measured as of the end of each calendar quarter. Under this provision, in any calendar quarter, the Advisor receives no incentive fee until pre-incentive fee net investment income equals the hurdle rate of 1.75%, but then receives, as a “catch-up,” 100.00% of the pre-incentive fee net investment income with respect to that portion of such pre-incentive fee net investment income, if any, that exceeds the hurdle rate but is less than 2.1875%. The effect of this provision is that, if pre-incentive fee net investment income exceeds 2.1875% in any calendar quarter, the Advisor will receive 20.00% of the pre-incentive fee net investment income as if the hurdle rate did not apply.

 

19
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

 

Pre-incentive fee net investment income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. Because of the structure of the incentive fee, it is possible that the Company may pay an incentive fee in a quarter in which the Company incurs a loss. For example, if the Company receives pre-incentive fee net investment income in excess of the quarterly minimum hurdle rate, the Company will pay the applicable incentive fee up to the Incentive Fee Cap, defined below, even if the Company has incurred a loss in that quarter due to realized and unrealized capital losses. The Company’s net investment income used to calculate this part of the incentive fee is also included in the amount of the Company’s gross assets used to calculate the 2.00% base management fee. These calculations are appropriately prorated for any period of less than three months and adjusted for any share issuances or repurchases during the current quarter.

 

Fee Cap and Deferral Mechanism. Commencing with the calendar quarter beginning July 1, 2014, the incentive fee on pre-incentive fee net investment income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three years and will be expensed when incurred. For this purpose, the look-back period for the incentive fee based on pre-incentive fee net investment income (the “Incentive Fee Look-back Period”) commenced on July 1, 2014 and will increase by one quarter in length at the end of each of the 12 succeeding calendar quarters, after which time, the Incentive Fee Look-back period will include the relevant calendar quarter and the 11 full preceding calendar quarters. Each quarterly Incentive Fee payable on pre-incentive fee net investment income is subject to a cap (the “Incentive Fee Cap”) and a deferral mechanism through which the Advisor may recoup a portion of such deferred incentive fees (collectively, the “Incentive Fee Cap and Deferral Mechanism”). The “Incentive Fee Cap” is equal to (a) 20.0% of Cumulative Pre-Incentive Fee Net Return (as defined below) during the Incentive Fee Look-back Period less (b) cumulative incentive fees of any kind paid to the Advisor during the Incentive Fee Look-back Period. To the extent the Incentive Fee Cap is zero or a negative value in any calendar quarter, the Company will not pay an incentive fee on pre-incentive fee net investment income to the Advisor in that quarter. To the extent that the payment of incentive fees on pre-incentive fee net investment income is limited by the Incentive Fee Cap, the payment of such fees will be deferred and paid in subsequent calendar quarters up to three years after their date of deferment, subject to certain limitations, which are set forth in the Investment Management Agreement. The Company only pays incentive fees on pre-incentive fee net investment income to the extent allowed by the Incentive Fee Cap and Deferral Mechanism. “Cumulative Pre-Incentive Fee Net Return” during any Incentive Fee Look-back Period means the sum of (a) pre-incentive fee net investment income and the base management fee for each calendar quarter during the Incentive Fee Look-back Period and (b) the sum of cumulative realized capital gains and losses, cumulative unrealized capital appreciation and cumulative unrealized capital depreciation during the applicable Incentive Fee Look-back Period.

 

The second part of the incentive fee is determined and payable in arrears as of the end of each calendar year (or, upon termination of the Investment Management Agreement, as of the termination date), and equals 20.00% of the Company’s realized capital gains, if any, on a cumulative basis from the date of the election to be a BDC through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis through the end of such year, less all previous amounts paid in respect of the capital gain incentive fee.

 

20
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

 

The performance based incentive fee expense was $0.8 million and $0.9 million for the three months ended September 30, 2014 and September 30, 2013, respectively. The performance based incentive fee expense was $1.2 million and $2.5 million for the nine months ended September 30, 2014 and 2013, respectively. The incentive fees payable as of September 30, 2014 and December 31, 2013 were $0.8 million and $0.9 million, respectively. The entire incentive fees payable as of September 30, 2014 and December 31, 2013 represented part one of the incentive fee.

 

Administration Agreement

 

The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s chief compliance officer and chief financial officer and their respective staffs. The administrative fee expense was $0.3 million for both the three months ended September 30, 2014 and 2013. The administrative fee expense was $0.9 million for both the nine months ended September 30, 2014 and 2013.

 

Note 4.  Investments

 

Investments, all of which are with portfolio companies in the United States, consisted of the following:

 

   September 30, 2014   December 31, 2013 
   Cost   Fair Value   Cost   Fair Value 
Money market funds  $800   $800   $1,188   $1,188 
Restricted investments in money market funds  $3,368   $3,368   $5,951   $5,951 
Non-affiliate investments                    
Debt  $195,956   $195,651   $223,054   $213,754 
Warrants   5,033    5,694    5,745    6,036 
Other Investments   4,645    300    4,729    400 
Equity   3,093    3,049    782    1,094 
Total non-affiliate investments  $208,727   $204,694   $234,310   $221,284 

 

The following table shows the Company’s portfolio investments by industry sector:

 

   September 30, 2014   December 31, 2013 
   Cost   Fair Value   Cost   Fair Value 
Life Science                    
Biotechnology  $16,972   $17,617   $17,604   $19,631 
Medical Device   25,118    24,498    20,079    14,972 
Technology                    
Communications   19,002    18,591    10,019    9,847 
Consumer-Related Technologies   4,099    4,632    118    435 
Data Storage   4,666    319    4,751    419 
Internet and Media   4,172    4,262    6,119    6,201 
Networking   1,043    1,039    1,025    1,034 
Power Management   7    58    14,382    13,101 
Semiconductors   32,446    32,330    37,897    37,793 
Software   54,544    55,548    67,510    67,869 
Cleantech                    
Alternative Energy   9,314    8,986    12,263    11,840 
Energy Efficiency   8,263    8,128    13,743    11,596 
Waste Recycling           2,294    680 
Healthcare Information and Services                    
Diagnostics   15,534    14,985    12,752    12,203 
Other Healthcare Related Services   7,146    7,196    7,384    7,190 
Software   6,401    6,505    6,370    6,473 
Total non-affiliate investments  $208,727   $204,694   $234,310   $221,284 

 

 

21
 

Horizon Technology Finance Corporation and Subsidiaries

 

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

 

Note 5.  Fair Value

 

The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no quoted market prices for certain assets or liabilities. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly, the fair value estimates may not be realized in an immediate settlement of the asset or liability.

 

Fair value measurements focus on exit prices in an orderly transaction (that is, not a forced liquidation or distressed sale) between market participants at the measurement date under current market conditions. If there has been a significant decrease in the volume and level of activity for the asset or liability, a change in valuation technique or the use of multiple valuation techniques may be appropriate. In such instances, determining the price at which willing market participants would transact at the measurement date under current market conditions depends on the facts and circumstances and requires the use of significant judgment.

 

The Company’s fair value measurements are classified into a fair value hierarchy based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The three categories within the hierarchy are as follows:

 

Level 1 Quoted prices in active markets for identical assets and liabilities.
   
Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities in active markets, quoted prices in markets that are not active, and model-based valuation techniques for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
   
Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

 

Investments are valued at fair value as determined in good faith by the Board, based on input of management, the audit committee and independent valuation firms, which are engaged at the direction of the Board to assist in the valuation of each portfolio investment lacking a readily available market quotation at least once during a trailing twelve-month period, under a valuation policy and a consistently applied valuation process. This valuation process is conducted at the end of each fiscal quarter, with 25% (based on fair value) of the Company’s valuation of portfolio companies lacking readily available market quotations subject to review by an independent valuation firm.

 

Because there is not a readily available market value for most of the investments in its portfolio, the Company values substantially all of its portfolio investments at fair value as determined in good faith by the Board, as described herein. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company's investments may fluctuate from period to period. Additionally, the fair value of the Company's investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values that the Company may ultimately realize. Further, such investments are generally subject to legal and other restrictions on resale or otherwise are less liquid than publicly traded securities. If the Company was required to liquidate a portfolio investment in a forced or liquidation sale, the Company could realize significantly less than the value at which the Company has recorded such portfolio investment.

 

Cash and interest receivable:  The carrying amount is a reasonable estimate of fair value. These financial instruments are not recorded at fair value on a recurring basis and are categorized as Level 1 within the fair value hierarchy described above.

 

22
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

 

Money Market Funds:  The carrying amounts are valued at their net asset value as of the close of business on the day of valuation. These financial instruments are recorded at fair value on a recurring basis and are categorized as Level 2 within the fair value hierarchy described above as these funds can be redeemed daily.

 

Debt Investments:  For variable rate debt investments which re-price frequently and have no significant change in credit risk, carrying values are a reasonable estimate of fair values. The fair value of fixed rate debt investments is estimated by discounting the expected future cash flows using the period end rates at which similar debt investments would be made to borrowers with similar credit ratings and for the same remaining maturities. At September 30, 2014 and December 31, 2013, the hypothetical market yield used ranged from 9% to 18% and from 9% to 25%, respectively. Significant increases (decreases) in this unobservable input would result in a significantly lower (higher) fair value measurement. These assets are recorded at fair value on a recurring basis and are categorized as Level 3 within the fair value hierarchy described above.

 

Under certain circumstances, the Company may use an alternative technique to value debt investments that better reflects its fair value such as the use of multiple probability weighted cash flow models when the expected future cash flows contain elements of variability. 

 

Warrant Investments:  The Company values its warrants using the Black-Scholes valuation model incorporating the following material assumptions:

 

Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement.

 

Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on indices of publicly traded companies similar in nature to the underlying company issuing the warrant. A total of seven such indices are used. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value investment.

 

The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant.

 

Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment. Significant increases (decreases) in this unobservable input would result in a significantly lower (higher) fair value measurement.

 

Historical portfolio experience on cancellations and exercises of the Company’s warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may be exercised in the event of acquisitions, mergers or IPOs, and cancelled due to events such as bankruptcies, restructuring activities or additional financings. These events cause the expected remaining life assumption to be shorter than the contractual term of the warrants. Significant increases (decreases) in this unobservable input would result in significantly higher (lower) fair value measurement.

 

Under certain circumstances the Company may use an alternative technique to value warrants that better reflects the warrants’ fair value, such as an expected settlement of a warrant in the near term or a model that incorporates a put feature associated with the warrant. The fair value may be determined based on the expected proceeds to be received from such settlement or based on the net present value of the expected proceeds from the put option. 

 

The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 within the fair value hierarchy described above. The fair value of the Company’s warrants held in private companies is determined using both observable and unobservable inputs and represents management’s best estimate of what market participants would use in pricing the warrants at the measurement date. Therefore, the Company has categorized these warrants as Level 3 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

 

23
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

 

Equity Investments: The fair value of an equity investment in a privately held company is initially the face value of the amount invested. The Company adjusts the fair value of equity investments in private companies upon the completion of a new third-party round of equity financing. The Company may make adjustments to fair value, absent a new equity financing event, based upon positive or negative changes in a portfolio company’s financial or operational performance. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. The Company has categorized these equity investments as Level 3 with the fair value hierarchy described above. The fair value of an equity investment in a publicly traded company is based upon the closing public share price on the date of measurement. Therefore, the Company has categorized these equity investments as Level 1 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

 

Other Investments: Other investments will be valued based on the facts and circumstances of the underlying agreement. The Company currently values one contractual agreement using a multiple probability weighted cash flow model as the contractual future cash flows contain elements of variability. Significant changes in the estimated cash flows and probability weightings would result in a significantly higher or lower fair value measurement. The Company has categorized this other investment as Level 3 within the fair value hierarchy described above. This asset is recorded at fair value on a recurring basis.

 

The following tables provide a summary of quantitative information about the Company’s Level 3 fair value measurements of its investments as of September 30, 2014 and December 31, 2013. In addition to the techniques and inputs noted in the table below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining its fair value measurements.

 

The table below is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements as of September 30, 2014:

 

September 30, 2014
   Fair   Valuation Techniques/  Unobservable      Weighted 
Investment Type  Value   Methodologies  Input  Range   Average 
Debt investments  $193,369   Discounted Expected Future Cash Flows  Hypothetical Market Yield   9% – 18%    11%
                      
    2,282   Multiple Probability Weighted Cash  Probability Weighting   30% – 40%    33%
        Flow Model             
                      
Warrant investments   4,044   Black-Scholes Valuation Model  Price per share   

$0.04 – $63.98

    $

3.70

 
           Average Industry Volatility   19%   19%
           Marketability Discount   20%   20%
           Estimated Time to Exit   1 to 5 years    3 years 
    512   Expected Settlement  Per Share Merger Consideration  $2.65   $2.65 
                      
Other investments   300   Multiple Probability Weighted Cash Flow Model  Discount Rate   25%   25%
           Probability Weighting   100%   100%
                      
Equity investments   2,300   Most Recent Equity Investment  Price Per Share  $0.20   $0.20 
    222   Market Comparable Companies  Price Per Share  $0.57   $0.57 
Total Level 3 investments   $203,029                 

  

24
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

 

The table below is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements as of December 31, 2013:

 

December 31, 2013
   Fair   Valuation Techniques/  Unobservable      Weighted 
Investment Type  Value   Methodologies  Input  Range   Average 
Debt investments  $199,815   Discounted Expected Future Cash Flows   Hypothetical Market Yield    

9% – 25% 

    11%
                      
    13,939   Multiple Probability Weighted Cash  Probability Weighting   10% – 100%    67%
        Flow Model             
                      
Warrant investments   4,579   Black-Scholes Valuation Model  Price per share   

$0.0 – $63.98

    $

3.48

 
           Average Industry Volatility   19%   19%
           Marketability Discount   20%   20%
           Estimated Time to Exit   1 to 10 years    3 years 
                      
Other investments   400   Multiple Probability Weighted Cash Flow Model  Discount Rate   25%   25%
           Probability Weighting   100%   100%
                      
Equity investments   529   Most Recent Equity Investment  Price Per Share   $1.09 – $1.50   $1.17 
Total Level 3 investments  $219,262                 

 

Borrowings:  The carrying amount of borrowings under the Credit Facilities (as defined in Note 6) approximates fair value due to the variable interest rate of the Credit Facilities and is categorized as Level 2 within the fair value hierarchy described above. Additionally, the Company considers its creditworthiness in determining the fair value of such borrowings. The fair value of the fixed rate 2019 Notes (as defined in Note 6) is based on the closing public share price on the date of measurement. At September 30, 2014, the 2019 Notes were trading on the New York Stock Exchange for $25.60 per note, or an aggregate of $33.8 million. Therefore, the Company has categorized this borrowing as Level 1 within the fair value hierarchy described above. Based on market quotations on September 30, 2014, the Asset-Backed Notes (as described in Note 6) were trading at par value, or $44.9 million, and are categorized as Level 3 within the fair value hierarchy described above. These liabilities are not recorded at fair value on a recurring basis.

 

Off-Balance-Sheet Instruments:  Fair values for off-balance-sheet lending commitments are based on fees currently charged to enter into similar agreements, taking into account the remaining terms of the agreements and the counterparties’ credit standings. Therefore, the Company has categorized these instruments as Level 3 within the fair value hierarchy described above.

 

The following tables detail the assets and liabilities that are carried at fair value and measured at fair value on a recurring basis as of September 30, 2014 and December 31, 2013 and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine the fair value:

 

   September 30, 2014 
   Total   Level 1   Level 2   Level 3 
Money market funds  $800   $   $800   $ 
Restricted investments in money market funds  $3,368   $   $3,368   $ 
Debt investments  $195,651   $   $   $195,651 
Warrant investments  $5,694   $   $1,138   $4,556 
Other investments  $300   $   $   $300 
Equity investments  $3,049   $527   $   $2,522 

 

   December 31, 2013 
   Total   Level 1   Level 2   Level 3 
Money market funds  $1,188   $   $1,188   $ 
Restricted investments in money market funds  $5,951   $   $5,951   $ 
Debt investments  $213,754   $   $   $213,754 
Warrant investments  $6,036   $   $1,457   $4,579 
Other investments  $400   $   $   $400 
Equity investments  $1,094   $565   $   $529 

 

25
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

  

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the three months ended September 30, 2014:

 

   Three Months Ended September 30, 2014 
   Debt
Investments
   Warrant
Investments
   Equity
Investments
   Other
Investments
   Total 
Level 3 assets, beginning of period  $209,197   $3,612   $2,522   $400   $215,731 
Purchase of investments   22,845                22,845 
Warrants and equity received and classified as Level 3       208            208 
Principal payments received on investments   (36,393)           (24)   (36,417)
Net realized loss on investments       (341)           (341)
Unrealized appreciation (depreciation)  included in earnings   4    1,077        (76)   1,005 
Other   (2)               (2)
Level 3 assets, end of period  $195,651   $4,556   $2,522   $300   $203,029 

 

The Company’s transfers between levels are recognized at the end of each reporting period. During the three months ended September 30, 2014, there were no transfers between levels.

 

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the three months ended September 30, 2013:

 

   Three Months Ended September 30, 2013 
   Debt
Investments
   Warrant
Investments
   Equity
Investments
   Other
Investments
   Total 
Level 3 assets, beginning of period  $237,871   $5,150   $529   $2,100   $245,650 
Purchase of investments   11,500                11,500 
Warrants and equity received and classified as Level 3       200            200 
Principal payments received on investments   (17,986)           (33)   (18,019)
Unrealized depreciation included in earnings   4,844    216        (67)   4,993 
Realized loss included in earnings   (5,010)   (270)           (5,280)
Other   422                422 
Level 3 assets, end of period  $231,661   $5,296   $529   $2,000   $239,486 

 

The Company’s transfers between levels are recognized at the end of each reporting period. During the three months ended September 30, 2013, there were no transfers between levels.

 

26
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

  

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the nine months ended September 30, 2014:

 

   Nine Months Ended September 30, 2014 
   Debt
Investments
   Warrant
Investments
   Equity
Investments
   Other
Investments
   Total 
Level 3 assets, beginning of period  $213,754   $4,579   $529   $400   $219,262 
Purchase of investments   66,823                66,823 
Warrants and equity received and classified as Level 3       468            468 
Principal payments received on investments   (83,821)           (85)   (83,906)
Proceeds from sale of investments       (929)           (929)
Net realized (loss) gain on investments   (8,096)   160            (7,936)
Unrealized appreciation (depreciation)  included in earnings   8,994    598    (198)   (15)   9,379 
Transfer out of Level 3       (320)   (109)       (429)
Transfer from debt to equity investments   (2,300)       2,300         
Other   297                297 
Level 3 assets, end of period  $195,651   $4,556   $2,522   $300   $203,029 

 

The Company’s transfers between levels are recognized at the end of each reporting period. During the nine months ended September 30, 2014, there were no transfers between Level 1 and Level 2. The transfer out of Level 3 relates to warrants held in two portfolio companies and equity held in one portfolio company, with an aggregate fair value of $0.4 million, that were transferred into Level 2 upon the portfolio companies becoming public companies during the period. Because the fair value of warrants and equity held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets, the Company has categorized the warrants and equity as Level 2 within the fair value hierarchy described above as of September 30, 2014. During the nine months ended September 30, 2014, there was one transfer between debt investments and equity investments. The transfer out of debt investments relates to the settlement of one of the Company’s debt investments for a cash payment of $2.7 million and $2.3 million in newly issued preferred stock of the applicable portfolio company.

 

The change in unrealized appreciation included in the consolidated statement of operations attributable to Level 3 investments still held at September 30, 2014 includes $0.1 million in unrealized appreciation for debt investments, $0.7 million in unrealized appreciation on warrants and $0.2 million in unrealized depreciation on equity.

 

27
 

 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

 

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the nine months ended September 30, 2013:

 

   Nine Months Ended September 30, 2013 
   Debt
Investments
   Warrant
Investments
   Equity
Investments
   Other
Investments
   Total 
Level 3 assets, beginning of period  $220,297   $4,914   $526   $2,100   $227,837 
Purchase of investments   69,143                69,143 
Warrants and equity received and classified as Level 3       626            626 
Principal payments received on investments   (55,921)           (33)   (55,954)
Proceeds from sale of warrants       (39)           (39)
Unrealized (depreciation) appreciation included in earnings   2,595    226    (70)   (67)   2,684 
Realized loss included in earnings   (5,010)   (315)           (5,325)
Transfer out of Level 3       (116)           (116)
Transfer from debt to equity investments   (73)       73         
Other   630                630 
Level 3 assets, end of period  $231,661   $5,296   $529   $2,000   $239,486 

 

The Company’s transfers between levels are recognized at the end of each reporting period. During the nine months ended September 30, 2013, there were no transfers between Level 1 and Level 2. The transfer out of Level 3 relates to warrants held in one portfolio company, with a fair value of $0.1 million, that were transferred into Level 2 due to the portfolio company becoming a public company during the nine months ended September 30, 2013. Because the fair value of warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets, the Company has categorized the warrants as Level 2 within the fair value hierarchy described above as of September 30, 2013.

 

The Company discloses fair value information about financial instruments, whether or not recognized in the statement of assets and liabilities, for which it is practicable to estimate that value. Certain financial instruments are excluded from the disclosure requirements. Accordingly, the aggregate fair value amounts presented do not represent the underlying value of the Company.

 

The fair value amounts have been measured as of the reporting date, and have not been reevaluated or updated for purposes of these financial statements subsequent to that date. As such, the fair values of these financial instruments subsequent to the reporting date may be different than amounts reported.

 

As of September 30, 2014 and December 31, 2013, the recorded balances equaled fair values of all the Company’s financial instruments, except for the Company’s 2019 Notes, as previously described.

 

Off-balance-sheet instruments

 

The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the fair values of the Company’s financial instruments will change when interest rate levels change, and that change may be either favorable or unfavorable to the Company. Management attempts to match maturities of assets and liabilities to the extent believed necessary to minimize interest rate risk. Management monitors rates and maturities of assets and liabilities and attempts to minimize interest rate risk by adjusting terms of new loans and by investing in securities with terms that mitigate the Company’s overall interest rate risk.

 

28
 

 

Horizon Technology Finance Corporation and Subsidiaries

 

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

 

Note 6.  Borrowings

 

A summary of the Company’s borrowings as of September 30, 2014 and December 31, 2013 is as follows:

 

   September 30, 2014   December 31, 2013 
   Total
Commitment
   Balance
Outstanding
   Unused
Commitment
   Total
Commitment
   Balance
Outstanding
   Unused
Commitment
 
Asset-Backed Notes  $44,902   $44,902   $   $79,343   $79,343   $ 
Fortress Facility               75,000    10,000    65,000 
Key Facility   50,000    10,000    40,000    50,000        50,000 
2019 Notes   33,000    33,000        33,000    33,000     
Total  $127,902   $87,902   $40,000   $237,343   $122,343   $115,000 

 

In accordance with the 1940 Act, with certain limited exceptions, the Company is only allowed to borrow amounts such that the Company’s asset coverage, as defined in the 1940 Act, is at least 200% after such borrowings. As of September 30, 2014, the asset coverage for borrowed amounts was 257%.

 

On November 4, 2013, the Company renewed and amended its revolving credit facility (referred to herein as the “Key Facility”) which it originally entered into with Wells Fargo Capital Finance, LLC, and facilitated the assignment of all rights and obligations thereunder to Key Equipment Finance (“Key”). The Key Facility has an accordion feature which allows for an increase in the total loan commitment to $150 million from the current $50 million commitment provided by Key. The Key Facility is collateralized by all loans and warrants held by Credit II and permits an advance rate of up to 50% of eligible loans held by Credit II. The Key Facility contains covenants that, among other things, require the Company to maintain a minimum net worth and to restrict the loans securing the Key Facility to certain criteria for qualified loans and includes portfolio company concentration limits as defined in the related loan agreement. The Key Facility has a three-year revolving period followed by a two-year amortization period and matures on November 4, 2018. The interest rate is based upon the one-month London Interbank Offered Rate (“LIBOR”) plus a spread of 3.25%, with a LIBOR floor of 0.75%. The rate at September 30, 2014 and December 31, 2013 was 4.00%. As of September 30, 2014, the Company had borrowing capacity of $40.0 million, of which $28.4 million was available, subject to existing terms and advance rates.

 

On March 23, 2012, the Company issued and sold an aggregate principal amount of $30 million of 7.375% senior unsecured notes due in 2019, and, on April 18, 2012, pursuant to the underwriters’ 30 day option to purchase additional notes, the Company sold an additional $3 million of such notes (collectively, the “2019 Notes”). The 2019 Notes will mature on March 15, 2019 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after March 15, 2015 at a redemption price of $25 per security plus accrued and unpaid interest. The 2019 Notes bear interest at a rate of 7.375% per year payable quarterly on March 15, June 15, September 15 and December 15 of each year. The 2019 Notes are the Company’s direct unsecured obligations and (i) rank equally in right of payment with the Company’s future senior unsecured indebtedness; (ii) are senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2019 Notes; (iii) are effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. As of September 30, 2014, the Company was in material compliance with the terms of the 2019 Notes. The 2019 Notes are listed on the New York Stock Exchange under the symbol “HTF.”

 

The Company entered into its Fortress Facility (together with the Key Facility, the “Credit Facilities”) with Fortress Credit Co LLC (“Fortress”) effective August 23, 2012. The Fortress Facility was collateralized by all loans and warrants held by Credit III. The Fortress Facility contained covenants that, among other things, required the Company to maintain a minimum net worth and restricted the loans securing the Fortress Facility to certain criteria for qualified loans and includes portfolio company concentration limits as defined in the related loan agreement. The Fortress Facility, among other things, had a three-year term subject to two one-year extensions with a draw period of up to four years. The Fortress Facility required the payment of an unused line fee in an amount equal to 1.00% of unborrowed amounts available under the facility annually and had an effective advance rate of 66% against eligible loans. The Fortress Facility bore interest based upon the one-month LIBOR plus a spread of 6.00%, with a LIBOR floor of 1.00%. The rate at December